Skip to main content

Biotech ETFs In Focus On String Of Q3 Earnings Beat

Though the biotech sector is down in October, it shows promise for the long-term due to a wave of mergers & acquisitions and a positive regulatory backdrop.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.